Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACONNASDAQ:ANPCNASDAQ:BGLCNASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$7.35+0.7%$7.37$6.20▼$3,499.51$4.33M1.2157,860 shs10,907 shsANPCFresh2 Group$4.37$4.92$2.60▼$11.99$4.24M1.5526,396 shs35,704 shsBGLCBioNexus Gene Lab$2.88-2.7%$2.92$2.01▼$8.40$5.33M5.6279,902 shs19,253 shsNTRANatera$167.55-0.4%$155.59$92.14▼$183.00$22.58B1.741.40 million shs899,351 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion-0.97%+1.52%+5.91%-64.01%-99.72%ANPCFresh2 Group0.00%0.00%0.00%0.00%0.00%BGLCBioNexus Gene Lab-2.70%-8.28%+1.05%-6.80%-36.00%NTRANatera-0.42%+1.41%+9.80%+11.06%+51.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACONAclarion2.3795 of 5 stars3.05.00.00.02.80.00.6ANPCFresh2 GroupN/AN/AN/AN/AN/AN/AN/AN/ABGLCBioNexus Gene Lab0.4047 of 5 stars0.03.00.00.03.30.00.0NTRANatera1.8622 of 5 stars2.52.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONAclarion 2.00Hold$11,758.50159,879.59% UpsideANPCFresh2 Group 0.00N/AN/AN/ABGLCBioNexus Gene Lab 0.00N/AN/AN/ANTRANatera 3.00Buy$184.6310.19% UpsideCurrent Analyst Ratings BreakdownLatest ANPC, BGLC, ACON, and NTRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025ACONAclarionAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy5/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.004/10/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$200.00 ➝ $160.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONAclarion$50K85.26N/AN/A$51.50 per share0.14ANPCFresh2 Group$1.75M2.42N/AN/A($1.41) per share-3.10BGLCBioNexus Gene Lab$9.27M0.56N/AN/A$4.63 per share0.62NTRANatera$1.70B13.48N/AN/A$9.05 per share18.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONAclarion-$6.99MN/A0.00N/AN/A-12,227.10%-126.89%-106.61%8/13/2025 (Estimated)ANPCFresh2 Group-$14.77MN/A0.00∞N/AN/AN/AN/AN/ABGLCBioNexus Gene Lab-$1.60MN/A0.00∞N/A-22.85%-24.18%-20.14%N/ANTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)Latest ANPC, BGLC, ACON, and NTRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACONAclarion-$1,447.20-$9.32+$1,437.88-$9.32$0.02 million$0.02 million5/15/2025Q1 2025BGLCBioNexus Gene LabN/A-$0.03N/A-$0.03N/AN/A5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONAclarionN/AN/AN/AN/AN/AANPCFresh2 GroupN/AN/AN/AN/AN/ABGLCBioNexus Gene LabN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONAclarionN/A2.802.80ANPCFresh2 GroupN/A0.320.32BGLCBioNexus Gene LabN/A4.973.99NTRANatera0.334.394.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONAclarion7.52%ANPCFresh2 Group45.84%BGLCBioNexus Gene Lab18.85%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipACONAclarion0.77%ANPCFresh2 Group26.22%BGLCBioNexus Gene Lab0.70%NTRANatera7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONAclarion7580,000578,000Not OptionableANPCFresh2 Group86970,000715,000Not OptionableBGLCBioNexus Gene Lab301.80 million1.78 millionNot OptionableNTRANatera4,434136.55 million126.17 millionOptionableANPC, BGLC, ACON, and NTRA HeadlinesRecent News About These CompaniesPrecision Wealth Strategies LLC Makes New $803,000 Investment in Natera, Inc. (NASDAQ:NTRA)June 16 at 7:34 AM | marketbeat.comElevation Point Wealth Partners LLC Sells 1,616 Shares of Natera, Inc. (NASDAQ:NTRA)June 16 at 4:06 AM | marketbeat.comHere's How Much You Would Have Made Owning Natera Stock In The Last 10 YearsJune 13, 2025 | benzinga.comHarbor Capital Advisors Inc. Sells 4,030 Shares of Natera, Inc. (NASDAQ:NTRA)June 13, 2025 | marketbeat.comGail Boxer Marcus Sells 4,000 Shares of Natera, Inc. (NASDAQ:NTRA) StockJune 12, 2025 | insidertrades.comNet Worth Advisory Group Takes Position in Natera, Inc. (NASDAQ:NTRA)June 12, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $60.92 Million Position in Natera, Inc. (NASDAQ:NTRA)June 12, 2025 | marketbeat.comHandelsbanken Fonder AB Boosts Stock Position in Natera, Inc. (NASDAQ:NTRA)June 12, 2025 | marketbeat.comWedmont Private Capital Makes New $223,000 Investment in Natera, Inc. (NASDAQ:NTRA)June 12, 2025 | marketbeat.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 4,000 Shares of StockJune 11, 2025 | marketbeat.comDuquesne Family Office LLC Decreases Stock Holdings in Natera, Inc. (NASDAQ:NTRA)June 11, 2025 | marketbeat.comRockingstone Advisors LLC Has $2.84 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)June 11, 2025 | marketbeat.comPallas Capital Advisors LLC Acquires 2,713 Shares of Natera, Inc. (NASDAQ:NTRA)June 11, 2025 | marketbeat.comNTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance IncreaseJune 10, 2025 | msn.comSG Americas Securities LLC Has $56.27 Million Stake in Natera, Inc. (NASDAQ:NTRA)June 10, 2025 | marketbeat.comLake Hills Wealth Management LLC Makes New $440,000 Investment in Natera, Inc. (NASDAQ:NTRA)June 7, 2025 | marketbeat.comMerit Financial Group LLC Has $1.33 Million Holdings in Natera, Inc. (NASDAQ:NTRA)June 7, 2025 | marketbeat.comRhumbline Advisers Has $21.69 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)June 7, 2025 | marketbeat.comE. Ohman J or Asset Management AB Sells 5,200 Shares of Natera, Inc. (NASDAQ:NTRA)June 6, 2025 | marketbeat.comGAMMA Investing LLC Buys 119,275 Shares of Natera, Inc. (NASDAQ:NTRA)June 6, 2025 | marketbeat.comNatera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 SharesJune 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANPC, BGLC, ACON, and NTRA Company DescriptionsAclarion NASDAQ:ACON$7.35 +0.05 (+0.68%) Closing price 06/17/2025 03:59 PM EasternExtended Trading$7.28 -0.07 (-0.90%) As of 06/17/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.Fresh2 Group NASDAQ:ANPCAnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.BioNexus Gene Lab NASDAQ:BGLC$2.88 -0.08 (-2.70%) Closing price 06/17/2025 03:59 PM EasternExtended Trading$2.97 +0.09 (+3.13%) As of 06/17/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.Natera NASDAQ:NTRA$167.55 -0.70 (-0.42%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$167.15 -0.40 (-0.24%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
